The artificial intelligence (AI)-Immunology powered cancer vaccine concept offers potential treatment solutions for patients who are unresponsive to standard cancer immunotherapies. Image Point Fr/Shutterstock.com.

Evaxion Biotech has announced plans to develop customised cancer vaccines by targeting a category of AI-discovered tumour antigens known as ERVs.

ERVs, which are ancient virus remnants dormant in human genomes, are often overexpressed in cancer cells but not in healthy tissue.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company’s AI platform, AI-Immunology, is pivotal in discovering these new types of cancer vaccine targets.

The technology enables the creation of customised and precision vaccine solutions, which are particularly promising for patients who are presently unresponsive to standard cancer immunotherapies.

The AI-Immunology powered vaccine concept also offers potential treatment solutions for these patients.

See Also:

Evaxion’s scalable AI prediction models utilise AI for decoding the human immune system and are instrumental in developing new immunotherapies for cancer, as well as bacterial and viral infections.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Using AI-Immunology, the company has developed a clinical-stage oncology pipeline of new personalised vaccines and a preclinical infectious disease pipeline addressing ailments with high unmet medical needs.

The preclinical activities have commenced, with proof-of-concept data anticipated in the second half of 2024.

Computational modelling of this scalable and adaptable AI technology platform rapidly detects, forecasts and creates vaccine candidates, offering a tailored approach to fight fast-evolving pathogens and malignant cells.

Evaxion chief scientific officer Birgitte Rønø stated: “With our intensified focus on ERV cancer vaccines, we aim to expedite the development process to deliver treatment solutions to cancer patients who, until now, have been deemed unresponsive to immunotherapy.

“The ERV cancer vaccine targets represent a promising breakthrough that could significantly broaden the horizons of cancer vaccine applicability and marks a significant step forward in our commitment to improving healthcare through innovative and AI-powered approaches. We are already seeing significant interest in ERV-based vaccines and look forward to further underpinning the significant potential by these proof-of-concept data.”